Prescriber Resources
POMALYST® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Enrolling in POMALYST REMS®
In order to prescribe POMALYST, you must enroll in the POMALYST REMS® program and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to the Celgene Customer Care at 1-888-432-9325.
Prescribing POMALYST for your patients
In order to receive POMALYST, your patients must also be enrolled in the POMALYST REMS® program. You can enroll your patients and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.
Additionally, you can also enroll your patients by accessing the Celgene REMS mobile app for your iPad.
Learning more about POMALYST REMS®
For additional information about the POMALYST REMS® program process, please see the educational materials below.
Please report adverse drug experiences that are suspected to be associated with the use of POMALYST and any suspected pregnancy occurring during the treatment with POMALYST to Celgene using any of the following methods:
REPORTING TO CELGENE |
|
Online: |
|
Email: |
|
Telephone: 1-908-673-9667 |
|
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or |
|
Fax: 1-908-673-9115 |
|
Mail to: Global Drug Safety & Risk Management |
|
Other: Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management |
REPORTING TO THE FDA |
|
Adverse drug experiences that are suspected to be associated with the use of POMALYST and any suspected pregnancy occurring during the treatment with POMALYST may also be reported to the FDA MedWatch Reporting System using any of the following methods: |
|
Online: |
|
Telephone: 1-800-FDA-1088 |
|
Fax: 1-800-FDA-0178 |
|
Mail to: MedWatch |
For additional information about the POMALYST REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
POMALYST® and POMALYST REMS® are registered trademarks of Celgene Corporation.
© 2013-2017. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
